Malaria – Gates Foundation Grants $23.6M for Gambia Tested Needle-free Vaccines
Earlier this year, Micron announced successful clinical data from a phase I/II study in the Gambia, which evaluated the safety, immunogenicity, and acceptability of the leading commercially available MR vaccine delivered by Micron’s microarray technology in adults, toddlers and infants as young as nine months old.